Redhill Biopharma (RDHL) Competitors $1.96 +0.05 (+2.36%) As of 01:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock RDHL vs. CING, MRKR, BIVI, QTTB, MTEX, PRPH, RVPH, CARM, LPCN, and GELSShould you be buying Redhill Biopharma stock or one of its competitors? The main competitors of Redhill Biopharma include Cingulate (CING), Marker Therapeutics (MRKR), BioVie (BIVI), Q32 Bio (QTTB), Mannatech (MTEX), ProPhase Labs (PRPH), Reviva Pharmaceuticals (RVPH), Carisma Therapeutics (CARM), Lipocine (LPCN), and Gelteq (GELS). These companies are all part of the "pharmaceutical products" industry. Redhill Biopharma vs. Its Competitors Cingulate Marker Therapeutics BioVie Q32 Bio Mannatech ProPhase Labs Reviva Pharmaceuticals Carisma Therapeutics Lipocine Gelteq Redhill Biopharma (NASDAQ:RDHL) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation. Is RDHL or CING more profitable? Redhill Biopharma's return on equity of 0.00% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Redhill BiopharmaN/A N/A N/A Cingulate N/A -229.78%-142.28% Do analysts prefer RDHL or CING? Cingulate has a consensus price target of $26.00, indicating a potential upside of 457.34%. Given Cingulate's stronger consensus rating and higher possible upside, analysts clearly believe Cingulate is more favorable than Redhill Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Redhill Biopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger earnings & valuation, RDHL or CING? Redhill Biopharma has higher revenue and earnings than Cingulate. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRedhill Biopharma$8.04M0.56-$8.27MN/AN/ACingulateN/AN/A-$15.55M-$8.48-0.55 Does the media favor RDHL or CING? In the previous week, Cingulate had 2 more articles in the media than Redhill Biopharma. MarketBeat recorded 3 mentions for Cingulate and 1 mentions for Redhill Biopharma. Redhill Biopharma's average media sentiment score of 1.87 beat Cingulate's score of 0.63 indicating that Redhill Biopharma is being referred to more favorably in the media. Company Overall Sentiment Redhill Biopharma Very Positive Cingulate Positive Which has more risk & volatility, RDHL or CING? Redhill Biopharma has a beta of 4.22, indicating that its share price is 322% more volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.79, indicating that its share price is 179% less volatile than the S&P 500. Do insiders and institutionals hold more shares of RDHL or CING? 7.2% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 6.8% of Redhill Biopharma shares are owned by insiders. Comparatively, 17.1% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryRedhill Biopharma and Cingulate tied by winning 6 of the 12 factors compared between the two stocks. Get Redhill Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RDHL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RDHL vs. The Competition Export to ExcelMetricRedhill BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.50M$2.44B$5.56B$9.30BDividend YieldN/A1.79%4.23%4.03%P/E RatioN/A9.1628.6119.64Price / Sales0.56735.94437.49188.30Price / CashN/A164.3436.0257.93Price / Book-0.534.688.185.63Net Income-$8.27M$30.99M$3.23B$257.73M7 Day Performance-6.28%0.57%-0.25%0.07%1 Month Performance9.83%7.91%5.40%8.32%1 Year Performance-99.22%-5.94%26.35%13.78% Redhill Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RDHLRedhill BiopharmaN/A$1.96+2.4%N/A-99.2%$4.50M$8.04M0.00210Positive NewsCINGCingulate3.2878 of 5 stars$4.42+3.3%$26.00+488.2%+1,032.8%$18.17MN/A-0.5220MRKRMarker Therapeutics4.4788 of 5 stars$1.57-1.9%$13.17+738.6%-71.8%$18.10M$6.59M-1.1860BIVIBioVie1.0605 of 5 stars$8.10-15.6%N/A+60.3%$17.83MN/A-1.0210Positive NewsGap UpQTTBQ32 Bio2.6783 of 5 stars$1.36-5.6%$12.17+794.6%-91.9%$17.57M$1.16M-0.2839MTEXMannatech1.3706 of 5 stars$8.90-3.8%N/A+14.8%$17.49M$117.87M-89.00250Positive NewsGap DownHigh Trading VolumePRPHProPhase Labs0.5379 of 5 stars$0.44+5.6%N/A-87.1%$17.39M$6.77M-0.35130Positive NewsGap DownRVPHReviva Pharmaceuticals3.2245 of 5 stars$0.37+1.9%$9.00+2,353.0%-68.1%$17.28MN/A-0.465Positive NewsCARMCarisma Therapeutics3.0084 of 5 stars$0.40-2.0%$1.93+387.3%-67.5%$16.84M$19.63M-0.2520Positive NewsLPCNLipocine3.0093 of 5 stars$3.11+0.3%$9.00+189.4%-58.0%$16.59M$11.20M-3.0510GELSGelteqN/A$1.67-2.9%N/AN/A$16.23M$100K0.00N/AGap Down Related Companies and Tools Related Companies Cingulate Competitors Marker Therapeutics Competitors BioVie Competitors Q32 Bio Competitors Mannatech Competitors ProPhase Labs Competitors Reviva Pharmaceuticals Competitors Carisma Therapeutics Competitors Lipocine Competitors Gelteq Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RDHL) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redhill Biopharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Redhill Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RDHL Stock Alerts